Combination of Ibrutinib and As2O3 in the Treatment of CLL

NCT02757040 Phase 3 UNKNOWN

The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia

Details

Lead sponsor	Peking University People's Hospital
Phase	Phase 3
Status	UNKNOWN
Enrolment	70
Start date	2016-12
Completion	2018-12

Conditions

• Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

• Ibrutinib combined with As2O3
• ibrutinib

Primary outcomes

• overall response rate — 2 years